Mirati Therapeutics initiated at B. Riley FBR
Mirati Therapeutics initiated with a Buy at B. Riley FBR. B. Riley FBR analyst Harshita Polishetty started Mirati Therapeutics with a Buy rating and $60 price target.https://thefly.com/landingPageNews.php?id=2830605
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.